Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847121 | 0.86 | GAA (0.42) | KMT2ATACR1GAA | |
| SCHEMBL12847110 | 0.81 | GAA (0.41) | KMT2AGAA | |
| SCHEMBL12790281 | 0.81 | GAA (0.39) | KMT2AGAA | |
| SCHEMBL12791022 | 0.79 | KMT2A (0.33) | KMT2AOPRM1GAA | |
| SCHEMBL13800155 | 0.72 | GAA (0.39) | KMT2AGAA | |
| SCHEMBL12847146 | 0.66 | GAA (0.41) | KMT2ATACR1GAA | |
| SCHEMBL12791064 | 0.66 | KMT2A (0.51) | KMT2ATACR1OPRM1 | |
| SCHEMBL12791101 | 0.65 | KMT2A (0.76) | KMT2A | |
| SCHEMBL12791190 | 0.63 | KMT2A (0.34) | KMT2ATACR1OPRM1 | |
| SCHEMBL12791029 | 0.62 | KMT2A (0.39) | KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065916-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065916-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | KMT2A 2911/4885TACR1 872/4885OPRM1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.